Companion diagnostic (CDx) tests play a critical role in personalising care by identifying optimal targeted therapies for patients based on their cancer’s unique genetic profile.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.